Observational Study in Parkinson's Disease of the Primary Care Population of Patients Treated With Pramipexole
NCT ID: NCT02236728
Last Updated: 2014-09-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
497 participants
OBSERVATIONAL
2008-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The secondary objectives were:
* Evaluate the mean dose of pramipexole prescribed under actual conditions of use depending on the severity of the disease.
* Evaluate the reasons for choosing pramipexole as treatment.
* Identify the patient profiles determining the choice of dose of pramipexole prescribed
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pramipexole in Untreated and Levodopa-treated Parkinson's Disease Patients
NCT02177357
Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms
NCT00297778
Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).
NCT00601523
Influence of Pramipexole Extended Release on Medication Adherence in Parkinson´s Disease
NCT01097421
A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients
NCT00402233
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Parkinson's disease patients
Pramipexole
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pramipexole
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patient taking part in a clinical trial
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boehringer Ingelheim
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
248.648
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.